Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.65 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359744 | 0.88 | CHUK (0.56) | KIF11CHUKMEN1KMT2AKDM4E | |
| SCHEMBL28280007 | 0.82 | ACHE (0.54) | KIF11KDM4EPDK2PDK4 | |
| SCHEMBL20685567 | 0.80 | KIF11 (0.53) | KIF11CHUKMEN1KMT2AKDM4E | |
| SCHEMBL10253400 | 0.79 | KIF11 (1.00) | KIF11CHUKMEN1KMT2AKDM4E | |
| SCHEMBL4421221 | 0.77 | CHUK (0.47) | CHUKPDK2PDK4 | |
| SCHEMBL20685571 | 0.77 | CHUK (0.47) | CHUKMEN1KMT2APDK2PDK4 | |
| SCHEMBL13598869 | 0.77 | PDK2 (0.43) | KDM4EPDK2PDK4 | |
| SCHEMBL18858401 | 0.76 | KIF11 (0.64) | KIF11CHUKMEN1KMT2AKDM4E | |
| SCHEMBL412032 | 0.75 | KIF11 (0.81) | KIF11CHUKMEN1KMT2AKDM4E | |
| SCHEMBL29507666 | 0.75 | KIF11 (0.81) | KIF11CHUKMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994577-B2 | Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity | MERCK PATENT GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9908863-B2 | Piperidinylcarbazoles | MERCK PATENT GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20170137428-A1 | AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137428-A1 | AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY | ACHE, PARK7, CYP51A1 | KIF11 1584/4885CHUK 4243/4885MEN1 343/4885 |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | PSEN1, ARG2, UQCRC1 | KIF11 3888/4885CHUK 4226/4885MEN1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.